{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T21:57:42Z","timestamp":1794952662082,"version":"4.9.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,9,24]],"date-time":"2018-09-24T00:00:00Z","timestamp":1537747200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,9,24]],"date-time":"2018-09-24T00:00:00Z","timestamp":1537747200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Understanding mechanisms of late\/acquired cancer immunotherapy resistance is critical to improve outcomes; cellular immunotherapy trials offer a means to probe complex tumor\u2013immune interfaces through defined T cell\/antigen interactions. We treated two patients with metastatic Merkel cell carcinoma with autologous Merkel cell polyomavirus specific CD8+ T cells and immune-checkpoint inhibitors. In both cases, dramatic remissions were associated with dense infiltration of activated CD8+s into the regressing tumors. However, late relapses developed at 22 and 18 months, respectively. Here we report single cell RNA sequencing identified dynamic transcriptional suppression of the specific HLA\u00a0genes presenting the targeted viral epitope in the resistant tumor as a consequence of intense CD8-mediated immunologic pressure; this is distinguished from genetic HLA-loss by its reversibility with drugs. Transcriptional suppression of Class I loci may underlie resistance to other immunotherapies, including checkpoint inhibitors, and have implications for the design of improved immunotherapy treatments.<\/jats:p>","DOI":"10.1038\/s41467-018-06300-3","type":"journal-article","created":{"date-parts":[[2018,9,18]],"date-time":"2018-09-18T09:24:17Z","timestamp":1537262657000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":284,"title":["Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA"],"prefix":"10.1038","volume":"9","author":[{"given":"K. G.","family":"Paulson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Voillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. S.","family":"McAfee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. S.","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. D.","family":"Wagener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Perdicchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9330-944X","authenticated-orcid":false,"given":"W. J.","family":"Valente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. J.","family":"Koelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. D.","family":"Church","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Vandeven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. G.","family":"Colunga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. G.","family":"Iyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Yee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Kulikauskas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1255-9023","authenticated-orcid":false,"given":"D. M.","family":"Koelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. H.","family":"Pierce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. H.","family":"Bielas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. D.","family":"Greenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3867-0232","authenticated-orcid":false,"given":"R.","family":"Gottardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2784-963X","authenticated-orcid":false,"given":"P.","family":"Nghiem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. G.","family":"Chapuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,24]]},"reference":[{"key":"6300_CR1","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMra1514296","volume":"375","author":"VA Boussiotis","year":"2016","unstructured":"Boussiotis, V. A. Molecular and biochemical aspects of the PD-1 checkpoint pathway. N. Engl. J. Med. 375, 1767\u20131778 (2016).","journal-title":"N. Engl. J. Med."},{"key":"6300_CR2","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","volume":"377","author":"JD Wolchok","year":"2017","unstructured":"Wolchok, J. D. et al. Overall survival with combined Nivolumab and Ipilimumab in advanced melanoma. N. Engl. J. Med. 377, 1345\u20131356 (2017).","journal-title":"N. Engl. J. Med."},{"key":"6300_CR3","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi, L. et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N. Engl. J. Med. 378, 2078\u20132092 (2018).","journal-title":"N. Engl. J. Med."},{"key":"6300_CR4","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-018-0693-y","volume":"20","author":"VS Koshkin","year":"2018","unstructured":"Koshkin, V. S. & Grivas, P. Emerging role of immunotherapy in advanced urothelial carcinoma. Curr. Oncol. Rep. 20, 48 (2018).","journal-title":"Curr. Oncol. Rep."},{"key":"6300_CR5","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma, P., Hu-Lieskovan, S., Wargo, J. A. & Ribas, A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168, 707\u2013723 (2017).","journal-title":"Cell"},{"key":"6300_CR6","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa1603702","volume":"374","author":"PT Nghiem","year":"2016","unstructured":"Nghiem, P. T. et al. PD-1 Blockade with pembrolizumab in advanced merkel-cell carcinoma. N. Engl. J. Med. 374, 2542\u20132552 (2016).","journal-title":"N. Engl. J. Med."},{"key":"6300_CR7","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert, C. et al. Pembrolizumab versus Ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521\u20132532 (2015).","journal-title":"N. Engl. J. Med."},{"key":"6300_CR8","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","volume":"171","author":"N Riaz","year":"2017","unstructured":"Riaz, N. et al. Tumor and microenvironment evolution during immunotherapy with Nivolumab. Cell 171, 934\u2013949.e915 (2017).","journal-title":"Cell"},{"key":"6300_CR9","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1604958","volume":"375","author":"JM Zaretsky","year":"2016","unstructured":"Zaretsky, J. M. et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. 375, 819\u2013829 (2016).","journal-title":"N. Engl. J. Med."},{"key":"6300_CR10","doi-asserted-by":"crossref","unstructured":"Chowell, D., et al. Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science\u00a0 359,\u00a0582\u2013587 (2017).","DOI":"10.1126\/science.aao4572"},{"key":"6300_CR11","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1126\/science.1152586","volume":"319","author":"H Feng","year":"2008","unstructured":"Feng, H., Shuda, M., Chang, Y. & Moore, P. S. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 319, 1096\u20131100 (2008).","journal-title":"Science"},{"key":"6300_CR12","doi-asserted-by":"publisher","first-page":"17077","DOI":"10.1038\/nrdp.2017.77","volume":"3","author":"JC Becker","year":"2017","unstructured":"Becker, J. C. et al. Merkel cell carcinoma. Nat. Rev. Dis. Prim. 3, 17077 (2017).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"6300_CR13","doi-asserted-by":"crossref","unstructured":"Paulson, K. G., et al. Merkel cell carcinoma: current United States incidence and projected increases based on changing demographics. J. Am. Acad. Dermatol.\u00a078, 457\u2013463.e2 (2018).","DOI":"10.1016\/j.jaad.2017.10.028"},{"key":"6300_CR14","doi-asserted-by":"crossref","unstructured":"D\u2019Angelo, S. P., et al. Efficacy and safety of first-line avelumab treatment in patients with stage IV metastatic Merkel cell carcinoma: a preplanned interim analysis of a clinical trial. JAMA Oncol. doi: 10.1001\/jamaoncol.2018.0077 (2018).","DOI":"10.1001\/jamaoncol.2018.0077"},{"key":"6300_CR15","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/S1470-2045(16)30364-3","volume":"17","author":"HL Kaufman","year":"2016","unstructured":"Kaufman, H. L. et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 17, 1374\u20131385 (2016).","journal-title":"Lancet Oncol."},{"key":"6300_CR16","doi-asserted-by":"publisher","first-page":"3403","DOI":"10.18632\/oncotarget.6494","volume":"7","author":"G Goh","year":"2016","unstructured":"Goh, G. et al. Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy. Oncotarget 7, 3403\u20133415 (2016).","journal-title":"Oncotarget"},{"key":"6300_CR17","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1158\/0008-5472.CAN-15-0702","volume":"75","author":"PW Harms","year":"2015","unstructured":"Harms, P. W. et al. The distinctive mutational spectra of polyomavirus-negative Merkel cell carcinoma. Cancer Res. 75, 3720\u20133727 (2015).","journal-title":"Cancer Res."},{"key":"6300_CR18","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1056\/NEJMc1713444","volume":"377","author":"M Yarchoan","year":"2017","unstructured":"Yarchoan, M., Hopkins, A. & Jaffee, E. M. Tumor mutational burden and response rate to PD-1 Inhibition. N. Engl. J. Med. 377, 2500\u20132501 (2017).","journal-title":"N. Engl. J. Med."},{"key":"6300_CR19","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1158\/2326-6066.CIR-16-0210","volume":"5","author":"NJ Miller","year":"2017","unstructured":"Miller, N. J. et al. Tumor-infiltrating Merkel cell polyomavirus-specific T cells are diverse and associated with improved patient survival. Cancer Immunol. Res 5, 137\u2013147 (2017).","journal-title":"Cancer Immunol. Res"},{"key":"6300_CR20","doi-asserted-by":"publisher","first-page":"6671","DOI":"10.1158\/1078-0432.CCR-11-1513","volume":"17","author":"JG Iyer","year":"2011","unstructured":"Iyer, J. G. et al. Merkel cell polyomavirus-specific CD8(+) and CD4(+) T-cell responses identified in Merkel cell carcinomas and blood. Clin. Cancer Res. 17, 6671\u20136680 (2011).","journal-title":"Clin. Cancer Res."},{"key":"6300_CR21","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1158\/2326-6066.CIR-13-0087","volume":"2","author":"AG Chapuis","year":"2014","unstructured":"Chapuis, A. G. et al. Regression of metastatic Merkel cell carcinoma following transfer of polyomavirus-specific T cells and therapies capable of re-inducing HLA class-I. Cancer Immunol. Res. 2, 27\u201336 (2014).","journal-title":"Cancer Immunol. Res"},{"key":"6300_CR22","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1158\/2326-6066.CIR-14-0005","volume":"2","author":"KG Paulson","year":"2014","unstructured":"Paulson, K. G. et al. Downregulation of MHC-I expression is prevalent but reversible in Merkel cell carcinoma. Cancer Immunol. Res. 2, 1071\u20131079 (2014).","journal-title":"Cancer Immunol. Res"},{"key":"6300_CR23","doi-asserted-by":"publisher","first-page":"3787","DOI":"10.1200\/JCO.2015.65.5142","volume":"34","author":"AG Chapuis","year":"2016","unstructured":"Chapuis, A. G. et al. T-cell therapy using interleukin-21-primed cytotoxic T-cell lymphocytes combined with cytotoxic T-cell lymphocyte antigen-4 blockade results in long-term cell persistence and durable tumor regression. J. Clin. Oncol. 34, 3787\u20133795 (2016).","journal-title":"J. Clin. Oncol."},{"key":"6300_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14049","volume":"8","author":"GX Zheng","year":"2017","unstructured":"Zheng, G. X. et al. Massively parallel digital transcriptional profiling of single cells. Nat. Commun. 8, 14049 (2017).","journal-title":"Nat. Commun."},{"key":"6300_CR25","first-page":"2579","volume":"9","author":"L van der Maaten","year":"2008","unstructured":"van der Maaten, L. & Hinton, G. Visualizing data using t-SNE. J. Mach. Learn. Res. 9, 2579\u20132605 (2008).","journal-title":"J. Mach. Learn. Res."},{"key":"6300_CR26","doi-asserted-by":"crossref","first-page":"597","DOI":"10.4049\/jimmunol.148.2.597","volume":"148","author":"CA Dahl","year":"1992","unstructured":"Dahl, C. A., Schall, R. P., He, H. L. & Cairns, J. S. Identification of a novel gene expressed in activated natural killer cells and T cells. J. Immunol. 148, 597\u2013603 (1992).","journal-title":"J. Immunol."},{"key":"6300_CR27","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1146\/annurev.immunol.26.021607.090347","volume":"26","author":"JK Burkhardt","year":"2008","unstructured":"Burkhardt, J. K., Carrizosa, E. & Shaffer, M. H. The actin cytoskeleton in T cell activation. Annu. Rev. Immunol. 26, 233\u2013259 (2008).","journal-title":"Annu. Rev. Immunol."},{"key":"6300_CR28","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.molimm.2015.07.026","volume":"68","author":"GM Delgoffe","year":"2015","unstructured":"Delgoffe, G. M. & Powell, J. D. Feeding an army: the metabolism of T cells in activation, anergy, and exhaustion. Mol. Immunol. 68, 492\u2013496 (2015).","journal-title":"Mol. Immunol."},{"key":"6300_CR29","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.1002\/eji.201343751","volume":"43","author":"YD Mahnke","year":"2013","unstructured":"Mahnke, Y. D., Brodie, T. M., Sallusto, F., Roederer, M. & Lugli, E. The who\u2019s who of T-cell differentiation: human memory T-cell subsets. Eur. J. Immunol. 43, 2797\u20132809 (2013).","journal-title":"Eur. J. Immunol."},{"key":"6300_CR30","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1200\/JCO.2010.30.6308","volume":"29","author":"KG Paulson","year":"2011","unstructured":"Paulson, K. G. et al. Transcriptome-wide studies of Merkel cell carcinoma and validation of intratumoral CD8 + lymphocyte invasion as an independent predictor of survival. J. Clin. Oncol. 29, 1539\u20131546 (2011).","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"6300_CR31","doi-asserted-by":"publisher","first-page":"eaal2568","DOI":"10.1126\/sciimmunol.aal2568","volume":"2","author":"Aude G. Chapuis","year":"2017","unstructured":"Chapuis, A. G., et al. Tracking the fate and origin of clinically relevant adoptively transferred CD8(+) T cells in vivo. Sci. Immunol. 2, eaal2568 (2017).","journal-title":"Science Immunology"},{"key":"6300_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-02608-0","volume":"7","author":"C Ritter","year":"2017","unstructured":"Ritter, C. et al. Epigenetic priming restores the HLA class-I antigen processing machinery expression in Merkel cell carcinoma. Sci. Rep. 7, 2290 (2017).","journal-title":"Sci. Rep."},{"key":"6300_CR33","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1609279","volume":"375","author":"E Tran","year":"2016","unstructured":"Tran, E. et al. T-cell transfer therapy targeting mutant KRAS in cancer. N. Engl. J. Med. 375, 2255\u20132262 (2016).","journal-title":"N. Engl. J. Med."},{"issue":"450","key":"6300_CR34","doi-asserted-by":"publisher","first-page":"eaar3342","DOI":"10.1126\/scitranslmed.aar3342","volume":"10","author":"Scott J. Rodig","year":"2018","unstructured":"Rodig, S. J., et al. MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma. Sci. Transl Med. 10, eaar3342 (2018).","journal-title":"Science Translational Medicine"},{"key":"6300_CR35","doi-asserted-by":"publisher","first-page":"4562","DOI":"10.1158\/0008-5472.CAN-16-3172","volume":"77","author":"M Donia","year":"2017","unstructured":"Donia, M. et al. Acquired immune resistance follows complete tumor regression without loss of target antigens or IFNgamma signaling. Cancer Res. 77, 4562\u20134566 (2017).","journal-title":"Cancer Res."},{"key":"6300_CR36","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1093\/nar\/21.5.1179","volume":"21","author":"LT Peltenburg","year":"1993","unstructured":"Peltenburg, L. T., Dee, R. & Schrier, P. I. Downregulation of HLA class I expression by c-myc in human melanoma is independent of enhancer A. Nucleic Acids Res. 21, 1179\u20131185 (1993).","journal-title":"Nucleic Acids Res."},{"key":"6300_CR37","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1093\/nar\/gkh340","volume":"32","author":"RC Edgar","year":"2004","unstructured":"Edgar, R. C. MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res. 32, 1792\u20131797 (2004).","journal-title":"Nucleic Acids Res."},{"key":"6300_CR38","doi-asserted-by":"publisher","first-page":"3245","DOI":"10.1200\/JCO.2006.06.5599","volume":"24","author":"CC Jaffe","year":"2006","unstructured":"Jaffe, C. C. Measures of response: RECIST, WHO, and new alternatives. J. Clin. Oncol. 24, 3245\u20133251 (2006).","journal-title":"J. Clin. Oncol."},{"key":"6300_CR39","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1158\/1078-0432.CCR-13-2697","volume":"20","author":"R Lyngaa","year":"2014","unstructured":"Lyngaa, R. et al. T-cell responses to oncogenic Merkel cell polyomavirus proteins distinguish patients with Merkel cell carcinoma from healthy donors. Clin. Cancer Res. 20, 1768\u20131778 (2014).","journal-title":"Clin. Cancer Res."},{"key":"6300_CR40","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1126\/science.1352912","volume":"257","author":"SR Riddell","year":"1992","unstructured":"Riddell, S. R., Watanabe, K. S., Goodrich, J. M., Li, C. R., Agha, M. E. & Greenberg, P. D. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 257, 238\u2013241 (1992).","journal-title":"Science"},{"key":"6300_CR41","doi-asserted-by":"publisher","first-page":"4099","DOI":"10.1182\/blood-2009-04-217604","volume":"114","author":"HS Robins","year":"2009","unstructured":"Robins, H. S. et al. Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells. Blood 114, 4099\u20134107 (2009).","journal-title":"Blood"},{"key":"6300_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3680","volume":"4","author":"CS Carlson","year":"2013","unstructured":"Carlson, C. S. et al. Using synthetic templates to design an unbiased multiplex PCR assay. Nat. Commun. 4, 2680 (2013).","journal-title":"Nat. Commun."},{"key":"6300_CR43","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1002\/ijc.24510","volume":"125","author":"M Shuda","year":"2009","unstructured":"Shuda, M. et al. Human Merkel cell polyomavirus infection I. MCV T antigen expression in Merkel cell carcinoma, lymphoid tissues and lymphoid tumors. Int. J. Cancer 125, 1243\u20131249 (2009).","journal-title":"Int. J. Cancer"},{"key":"6300_CR44","doi-asserted-by":"publisher","first-page":"e164","DOI":"10.1093\/nar\/gkq603","volume":"38","author":"K Wang","year":"2010","unstructured":"Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 38, e164 (2010).","journal-title":"Nucleic Acids Res."},{"key":"6300_CR45","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nbt.2514","volume":"31","author":"K Cibulskis","year":"2013","unstructured":"Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213\u2013219 (2013).","journal-title":"Nat. Biotechnol."},{"key":"6300_CR46","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","volume":"25","author":"H Li","year":"2009","unstructured":"Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows\u2013Wheeler transform. Bioinformatics 25, 1754\u20131760 (2009).","journal-title":"Bioinformatics"},{"key":"6300_CR47","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1101\/gr.107524.110","volume":"20","author":"A McKenna","year":"2010","unstructured":"McKenna, A. et al. The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297\u20131303 (2010).","journal-title":"Genome Res."},{"key":"6300_CR48","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"6300_CR49","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nbt.3192","volume":"33","author":"R Satija","year":"2015","unstructured":"Satija, R., Farrell, J. A., Gennert, D., Schier, A. F. & Regev, A. Spatial reconstruction of single-cell gene expression data. Nat. Biotechnol. 33, 495\u2013502 (2015).","journal-title":"Nat. Biotechnol."},{"key":"6300_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-015-0844-5","volume":"16","author":"G Finak","year":"2015","unstructured":"Finak, G. et al. MAST: a flexible statistical framework for assessing transcriptional changes and characterizing heterogeneity in single-cell RNA sequencing data. Genome Biol. 16, 278 (2015).","journal-title":"Genome Biol."},{"key":"6300_CR51","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nbt.4096","volume":"36","author":"A Butler","year":"2018","unstructured":"Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 36, 411\u2013420 (2018).","journal-title":"Nat. Biotechnol."},{"key":"6300_CR52","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1016\/j.cell.2015.05.002","volume":"161","author":"EZ Macosko","year":"2015","unstructured":"Macosko, E. Z. et al. Highly parallel genome-wide expression profiling of individual cells using nanoliter droplets. Cell 161, 1202\u20131214 (2015).","journal-title":"Cell"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-06300-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-06300-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-06300-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T05:51:55Z","timestamp":1693893115000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-06300-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,24]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["6300"],"URL":"https:\/\/doi.org\/10.1038\/s41467-018-06300-3","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,24]]},"assertion":[{"value":"11 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.G. Chapuis has received support from Juno therapeutics. P.D.G. has received support and has ownership interest in Juno Therapeutics, Immune Design, and Innate Pharma. P.N. has received consulting fees from EMD Serono, Pfizer, Merck Sharpe and Dohne, Amgen, Incyte, Takeda, Mallinckrodt and research support from EMD Serono and Bristol-Meyers Squibb. A.G.C., M.S.M., D.M.K., K.G.P., C.D.C., and P.N. and their institutions have intellectual property related to T cell receptors recognizing Merkel cell polyomavirus. S.B. has received advisory board honoraria from Genentech and EMD-Serono; his institution (University of Washington) has received research funding from EMD-Serono, Merck, BMS, Oncosec, and Immune Design. A.G. Chapuis and K.G.P. have received reagents from 10X genomics. R.G. received consulting fees from Juno Therapeutics. The authors declare no other competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"3868"}}